Alexion Receives Orphan Drug Status For Dermatomyositis Treatment

The FDA has granted Orphan Drug status to Alexion Pharmaceuticals, Inc.’s humanized monoclonal antibody C5 Complement Inhibitor 5G1.1 for the treatment of patients with dermatomyositis. Alexion is currently enrolling patients in a Phase Ib pilot clinical trial that is designed to gather clinical data regarding the safety profile and biological and clinical effects of 5G1.1 Read more about Alexion Receives Orphan Drug Status For Dermatomyositis Treatment[…]

Curagen And Gemini Enter Genome Wide Drug Target Discovery And Pharmacogenetics Collaboration

CuraGen Corporation, an integrated genomics based drug discovery and development company, and Gemini Genomics plc, announced today the largest collaboration to date linking cSNPs (human genetic variations) and clinical information to identify and validate novel drug targets for use in the discovery and development of pharmaceutical and diagnostic products. Specifically, CuraGen and Gemini scientists will Read more about Curagen And Gemini Enter Genome Wide Drug Target Discovery And Pharmacogenetics Collaboration[…]

Millennium And Morphosys Extend Collaboration

Millennium Pharmaceuticals, Inc. has signed an agreement for an expanded alliance with MorphoSys AG. Under their agreement, MorphoSys AG will apply its proprietary HuCAL technology to generate human antibodies for a new target molecule in inflammatory disorders provided by Millennium. One of the objectives of the alliance is to develop fully human antibodies against targets Read more about Millennium And Morphosys Extend Collaboration[…]

Pharmagenesis, Inc.

Fujisawa Enters Research Agreement With Pharmagenesis

Fujisawa Pharmaceutical Co., Ltd., has executed a collaborative research agreement with Pharmagenesis, Inc., with regard to triptolide derivatives, novel and potent immunosuppressants created by Pharmagenesis. The agreement also gives Fujisawa an option to acquire the exclusive and worldwide (certain territories are under negotiation) development and marketing rights to Pharmagenesis’ compounds in the therapeutic areas of Read more about Fujisawa Enters Research Agreement With Pharmagenesis[…]

Buy Dragon Pharmaceuticals Ready for Use

Winstrol Tabs - Bulk Price

Administration: Oral
Principal Constituent: Stanozolol
Branded by: Dragon Pharma
Unit: 10 x 100 tabs (50 mg/tablet)
Price: 10 x $63.00

Propionat 100

Injectable Anabolic Steroid
Basic Ingredient: Testosterone Propionate
Branded by: Dragon Pharma Labs
Pack: 1 X 10 ml (100 mg/ml)

Primobolan 100

Injectable Anabolic Steroid
Basal Chemical Name: Methenolone Enanthate
Producer: Dragon Pharmaceutical
Package: 1 X 10 ml (100 mg/ml)

NPP 150 - Bulk Price

Administration: Injection
Basal Ingredient: Nandrolone Phenylpropionate
Made by: Dragon Pharmaceuticals
Amount: 10 x 10 mL vial (150 mg/mL)
Price: 10 x $30.00


Natural Anabolic Steroidal Agent
Basal Component: Methandrostenolone
Manufacturer: Dragon Pharma
Amount: 1 X 100 pills (20 mg/tablet)

Deca 500

Injectable Anabolic Steroid
Base Chemical Name: Nandrolone Decanoate
Manufacturer: Dragon Pharma Labs
Amount: 1 X 10 ml (500 mg/ml)


Beta-2 Agonist, Bronchodilator
Primary Ingredient: Clenbuterol Hydrochloride
Branded by: Dragon Pharma Labs
Package: 1 X 100 pills (40 mcg/pastille)


Oral Steroid for Muscle Growth
Basal Constituent: Oxymetholone
Made by: Dragon Pharma
100 pastilles (50 mg/pill)


Base Constituent: Clenbuterol Hydrochloride
Made by: Dragon Pharma
Amount: 100 tabs (40 mcg/pill)

Propionat 100 [10 Vials]

Injectable Steroid for Muscle Growth
Main Chemical Name: Testosterone Propionate
Produced by: Dragon Pharma Labs
10 Vials [10 mL per Vial (100 mg/ml)]
Price: 10 x $30.00 = $300.00 in Total

Winstrol Tabs Cheap Priced

Oral Anabolic Steroid
Main Component: Stanozolol
Made by: Dragon Pharma LLC
Amount: 20 x 100 tabs (50 mg/tablet)
Price per Amount: 58.00 USD


Manufacturer: Dragon Pharma Labs
Main Ingredient: Methandrostenolone
Unit: 100 tablets (20 mg/pill)